Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors.
We aim to investigate long-term survival outcomes in patients undergoing radiofrequency ablation (RFA), based on our longitudinal 5 and 10 year follow-up data.



All patients who underwent RFA for hepatocellular carcinoma (HCC) and colorectal liver metastasis (CLM) between 1999 and 2010.



320 patients were included with oncologic diagnoses of HCC in 122 (38.1%) and CLM in 198 (61.9%). The majority of patients had a single tumor ablation (71% RFA 1 lesion). Minimum 5 year follow-up information was available in 89% patients, with a median follow-up of 115.3 months. In patients with HCC, disease eventually recurred in 73 (64%) patients. In patients with CLM, disease recurrence was ultimately seen in 143 (84.1%) patients. In the HCC group, the 5- and 10-year overall survivals were 38.5% and 23.4%, while in the CLM group, the 5- and 10-year overall survivals were 27.6% and 15%, respectively.



The use of RFA as a part of treatment strategy for primary and metastatic liver tumors imparts 10-year overall survivals of >23% and 15%, respectively. This study indicates that long-term survival is possible with RFA treatment.
University of Pittsburgh Medical Center/UPMC Liver Cancer Center, Pittsburgh, PA, United States. Electronic address: sucandyi2@upmc.edu.
Iswanto
I
Sucandy
University of Pittsburgh Medical Center/UPMC Liver Cancer Center, Pittsburgh, PA, United States.
Susannah
S
Cheek
NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY, United States.
Benjamin J
BJ
Golas
University of Pittsburgh Medical Center/UPMC Liver Cancer Center, Pittsburgh, PA, United States.
Allan
A
Tsung
University of Pittsburgh Medical Center/UPMC Liver Cancer Center, Pittsburgh, PA, United States.
David A
DA
Geller
University of Pittsburgh Medical Center/UPMC Liver Cancer Center, Pittsburgh, PA, United States.
James W
JW
Marsh
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D017115:Catheter Ablation / Q000009:adverse effects / Q000401:mortality; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome